journal article·2024-02Open access

Multifunctional graphene quantum dots: A therapeutic strategy for neurodegenerative diseases by regulating calcium influx, crossing the blood-brain barrier and inhibiting Aβ-protein aggregation

I. Jénnifer Gómez, Petra Křížková, Anna Dolečková, Lucía Cardo, Cecilia Wetzl, Naděžda Pizúrová, Maurizio Prato, Jiřina Medalová, Lenka Zajíčková

Abstract

Multifunctional nanoparticles could be the hallmark for the treatment of neurodegenerative diseases. Dissociation of protein aggregates causing neuronal damage and transfer of specific drugs which can downregulate neuronal excitotoxicity by inhibiting glutamatergic N-Methyl-d-Aspartate-receptors (NMDA) and then reducing calcium influx are among the main factors to consider for proper therapy. Here, we present a multiplatform based on nitrogen-doped graphene quantum dots (NGQDs) with such functionalities. The NGQDs were functionalized with Memantine, the clinically used drug, via covalent and non-covalent coupling, and we confirmed that the pharmaceutical activity was not altered. Apart from that, using xCELLigence technology and flow cytometric analysis of ABC transporter function, we uncovered that the ABC transporters of the blood-brain barrier (BBB) do not affect the ability of NGQD to cross BBB. Surprisingly, this study found that NGQDs have an inhibitory effect on NMDA receptors, thus supporting the action of Memantine. Moreover, NGQDs and their derivatives demonstrated the potential to dissociate β-amyloid aggregates while possessing features suitable for bioimaging in various cell lines.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Carbon and Quantum Dots Applications · Nanocluster Synthesis and Applications · Graphene and Nanomaterials Applications

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (62)

Show source-provided references
1. Converging pathways in neurodegeneration, from genetics to mechanisms10.1038/s41593-018-0237-7 ↗
2. Toxic proteins in neurodegenerative disease
3. The role of glutamate transporters in neurodegenerative diseases and potential opportunities for intervention10.1016/j.neuint.2007.03.012 ↗
4. The neuropharmacological basis for the use of memantine in the treatment of Alzheimer's disease10.1111/j.1527-3458.2003.tb00254.x ↗
5. ABC transporters are key players in Alzheimer's disease10.3233/JAD-170639 ↗
6. Nanocarriers as potential drug delivery candidates for overcoming the blood-brain barrier: challenges and possibilities10.1021/acsomega.0c01592 ↗
7. Carbon nanostructures: the drug and the delivery system for brain disorders10.1016/j.ijpharm.2020.119701 ↗
8. Carbon nanotubes for delivery of small molecule drugs10.1016/j.addr.2013.08.005 ↗
9. Carbon nanotube inhibits the formation of β-sheet-rich oligomers of the Alzheimer's amyloid-β(16-22) peptide10.1016/j.bpj.2011.09.046 ↗
10. Multiwalled carbon nanotubes induced hypotension by regulating the central nervous system10.1002/adfm.201705479 ↗
11. The interaction of carbon nanotubes with an invitro blood-brain barrier model and mouse brain invivo10.1016/j.biomaterials.2015.02.083 ↗
12. Understanding the toxicity of carbon nanotubes10.1021/ar300028m ↗
13. Toxicity of carbon nanotubes: a review10.1177/0748233717747472 ↗
14. Carbon nanotubes and graphene as emerging candidates in neuroregeneration and neurodrug delivery
15. Reduced graphene oxide induces transient blood-brain barrier opening: an in vivo study10.1186/s12951-015-0143-z ↗
16. Carbon nano onions cross the blood brain barrier†10.1039/C5RA23534K ↗
17. Carbon nano-onions: a review of recent progress in synthesis and applications10.1002/cnma.201800583 ↗
18. Carbon nanomaterials for biomedical applications10.1201/9781351123587-7 ↗
19. Semiconductor and carbon-based fluorescent nanodots: the need for consistency10.1039/C5CC07754K ↗
20. A multifunctional chemical toolbox to engineer carbon dots for biomedical and energy applications10.1038/s41565-021-01051-7 ↗
21. Carbon Nanodots: nanolights Illuminating a Bright Future10.1002/smll.202304703 ↗
22. The formation mechanism and fluorophores of carbon dots synthesized: via a bottom-up route10.1039/C9QM00552H ↗
23. Design, synthesis, and functionalization strategies of tailored carbon nanodots10.1021/acs.accounts.9b00249 ↗
24. Electrophoretic analysis and purification of fluorescent single-walled carbon nanotube fragments10.1021/ja040082h ↗
25. Carbon quantum dots and their applications10.1039/C4CS00269E ↗
26. Glowing graphene quantum dots and carbon dots: properties, syntheses, and biological applications10.1002/smll.201402648 ↗
27. Carbon dots: a new type of carbon-based nanomaterial with wide applications10.1021/acscentsci.0c01306 ↗
28. Structure elucidation of multicolor emissive graphene quantum dots towards cell guidance10.1039/D1QM01126J ↗
29. Carbon dots: synthesis, properties and biomedical applications10.1039/D1TB01077H ↗
30. Crossing the blood–brain barrier with carbon dots: uptake mechanism and in vivo cargo delivery10.1039/D1NA00145K ↗
31. Carbon dots: a future blood–brain barrier penetrating nanomedicine and drug nanocarrier10.2147/IJN.S318732 ↗
32. Organotin(IV)-Decorated Graphene Quantum Dots as Dual Platform for Molecular Imaging and Treatment of Triple Negative Breast Cancer10.1002/chem.202301845 ↗
33. Exploring the emission pathways in nitrogen-doped graphene quantum dots for bioimaging10.1021/acs.jpcc.1c06029 ↗
34. An inverted blood-brain barrier model that permits interactions between glia and inflammatory stimuli10.1016/j.jneumeth.2012.03.015 ↗
35. Cell-based in vitro blood – brain barrier model can rapidly evaluate nanoparticles ’ Brain permeability in association with particle size and surface modification10.3390/ijms15021812 ↗
36. Graphene quantum dots prevent α-synucleinopathy in Parkinson's disease10.1038/s41565-018-0179-y ↗
37. Graphene quantum dots for the inhibition of β amyloid aggregation10.1039/C5NR06282A ↗
38. Gwyddion: an open-source software for SPM data analysis
39. Coupling BODIPY with nitrogen-doped graphene quantum dots to address the water solubility of10.1039/D2QM00200K ↗
40. Nitrogen-doped Carbon Nanodots for bioimaging and delivery of paclitaxel10.1039/C8TB01796D ↗
41. Crystalline F-doped titanium dioxide nanoparticles decorated with graphene quantum dots for improving the photodegradation of water pollutants10.1016/j.jphotochem.2023.114875 ↗
42. Supramolecular chemistry of carbon-based dots offers widespread opportunities10.1002/smll.202300906 ↗
43. Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system - too little activation is bad, too much is even worse10.1016/j.neuropharm.2007.07.013 ↗
44. The dichotomy of memantine treatment for ischemic stroke: dose-dependent protective and detrimental effects10.1038/jcbfm.2014.188 ↗
45. Multifunctional memantine nitrate significantly protects against glutamate-induced excitotoxicity via inhibiting calcium influx and attenuating PI3K/Akt/GSK3beta pathway10.1016/j.cbi.2020.109020 ↗
46. NMDA receptors in astrocytes: in search for roles in neurotransmission and astrocytic homeostasis10.3390/ijms20020309 ↗
47. Neuromodulatory properties of fluorescent carbon dots: effect on exocytotic release, uptake and ambient level of glutamate and GABA in brain nerve terminals10.1016/j.biocel.2014.11.016 ↗
48. Nitrogen-Doped Arginine Carbon Dots and Its Metal Nanoparticle Composites as Antibacterial Agent10.3390/c6030058 ↗
49. The endocytic pathways of carbon dots in human adenoid cystic carcinoma cells10.1111/cpr.12586 ↗
50. Cell response to carbon nanotubes: size-dependent intracellular uptake mechanism and subcellular fate10.1002/smll.201001260 ↗
51. Elucidating the endocytosis, intracellular trafficking, and exocytosis of carbon dots in neural cells
52. Photoluminescence mechanism of carbon dots: triggering high-color-purity red fluorescence emission through edge amino protonation10.1038/s41467-021-27071-4 ↗
53. K. Solly, X. Wang, X. Xu, B. Strulovici, W. Zheng, Application of real-time cell electronic sensing (RT-CES) technology to cell-based assays, 2004.10.1089/1540658041850544 ↗
54. Kinetic cell-based morphological screening: prediction of mechanism of compound action and off-target effects10.1016/j.chembiol.2009.05.011 ↗
55. P-glycoprotein (ABCB1) and oxidative stress: focus on Alzheimer⇔s disease
56. Blood-brain barrier active efflux transporters: ATP-Binding cassette Gene family10.1602/neurorx.2.1.86 ↗
57. Regulation of ABC transporters at the blood–brain barrier10.1002/cpt.64 ↗
58. Regulations of P-Glycoprotein/ABCB1/MDR1 in human cancer cells10.1155/2014/476974 ↗
59. ABCB1: the role in Parkinson's disease and pharmacokinetics of antiparkinsonian drugs10.1517/17425250903193079 ↗
60. Blood–brain barrier transporters: opportunities for therapeutic development in ischemic stroke10.3390/ijms23031898 ↗
61. A.E. Roher, J.D. Lowensont, S. Clarket, A.S. Woods, R.J. Cotter, E. Gowing, M.J. Ball, Beta-Amyloid-(1-42)is a major component of cerebrovascular amyloid deposits: implications for the pathology of Alzheimer disease (cerebrovasculature/blood brain barrier), 1993.10.1073/pnas.90.22.10836 ↗
62. Structures for amyloid fibrils10.1111/j.1742-4658.2005.05025.x ↗